Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Semler Scientific (SMLR)
Quote:Semler Scientific initiated with a Buy at B. Riley FBR B. Riley FBR analyst Josh Nichols initiated coverage of Semler Scientific with a Buy rating and $61 price target. The company's patented QuantaFlo product, which acts as an early detection test for peripheral arterial disease, has seen a significant increase in usage and a growing installed base since gaining FDA approval in March 2015, Nichols tells investors in a research note. While Semler is "significantly profitable" with 35%-plus EBITDA margins and 89% sales growth in 2019, the company has "flown under the radar," in part due to its smaller size and over-the-counter listing, adds the analyst. Nichols views the shares as "materially undervalued."
Semler Scientific initiated with a Buy at B. Riley FBR SMLR - The Fly
  • This came out on June 23 but we beat them to it, our June 12:
Quote:The company has simplified the testing of PAD, which is a marker for increased risk of stroke and cardiovascular disease. It runs on a capital light, license fee business model that generates high margins and substantial cash flows. The pandemic has interrupted the progress, but the company seems well placed to weather the storm.
Semler Scientific: A Little Gem Of A Company (OTCMKTS:SMLR) | Seeking Alpha

Forum Jump:

Users browsing this thread: 1 Guest(s)